Aesthetic pharmaceutical company Croma Pharma has launched new self-occluding topical local anaesthetic cream Pliaglis.
According to the company, the cream has been approved in its European core markets including Germany, the UK and Ireland, with additional markets including Brazil to follow by the end of 2023.
Specifically designed and licensed for anaesthetic needs in aesthetic medicine, Pliaglis is applied by the practitioner before a range of minimally invasive aesthetic procedures such as dermal filler and collagen injections or laser treatments. The cream aims to protect the patient and reduce pain associated with these procedures, adds Croma Pharma.
The company explains that Pliaglis is the only licensed topical anaesthetic cream that combines the highest registered concentration of lidocaine (7%) and tetracaine (7%) in a self-occluding formula. The formulation starts to work as early as 30 minutes after application, with a duration of up to 13 hours.
The safety of Pliaglis was evaluated in 12 phase III, randomised, double-blind, placebo-controlled clinical studies including a total of 669 adult patients, before various dermatologic procedures. Localised skin reactions were generally mild and transient in nature. Systemic adverse reactions are unlikely due to the small doses of lidocaine and tetracaine that are absorbed.
